DOCSLIB.ORG

Updated-Final List of Pharma Product Patents During 2005-06 to 2009-10

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Updated-Final List of Pharma Product Patents During 2005-06 to 2009-10 Product Patents in Pharmaceuticals granted by Indian Patent Office during 2005-06 to 2009-10 * Patent Title S No Application No Patent No Applicant Grant Date A NOVEL [6,7-BIS(2-ETHOXYETHOXY) QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL) 1 537/DEL/1996 196774 23-02-2007 PFIZER PRODUCTS, INC. AMINE HYDROCHLORIDE AND A PROCESS FOR PREPARING THE SAME A SYNERGISTIC ANTIBACTERIAL 2 178/MUM/2004 197822 19/12/2005 FORMULATION AND TO A METHOD OF SANJEEV KHANDELWAL MAKING THE SAME NOVEL INJECTABLE ANTIMALERIAL 3 738/BOM/1999 198002 01-03-2006 DR. DINESH SHANTILAL PATEL COMPOSITIONS OF ARTEMISININ A SYNERGISTIC AQUEOUS PHARMACEUTICAL 4 488/MUM/2000 198178 01-09-2006 COMPOSITION FOR PROPHYLACTIC LUPIN LABORATORIES LTD TREATMENT OF MIGRAINE A NOVEL PHARMACEUTICAL COMPOSITION 5 890/MUM/2003 198771 06-02-2006 OF A PROTON PUMP INHIBITOR WITH A ARISTO PHARMACEUTICAL LTD PROKINETIC AGENT 3-AZABICYCLO [3,1,0] HEXANE DERIVATIVES 6 811/BOM/1999 200054 15/04/2006 PFIZER INC USEFUL IN THERAPY IMIDAZO PYRIDINE DERIVATIVES AND A 7 IN/PCT/2000/497/MUM 200057 17/04/2006 ASTRAZENECA AB PROCESS THEREOF 8 IN/PCT/2001/1296/MUM 200062 15/04/2006 A COMPOUND OF FORMULA (I) AMERICAL HOME PRODUCT CORP. COMPOUNDS OF THIAZOLYL AMIDE 9 IN/PCT/2002/774/MUM 200067 15/04/2006 BAYER AKTIENGESELLSCHAFT DERIVATIVES A 2- OXO-1-PYRROLIDINE COMPOUND OR 10 IN/PCT/2002/1000/MUM 200075 17/04/2006 UCB SA PHARMA-CEUTICAL SALTS 11 IN/PCT/2001/67/KOL 200123 01-12-2006 MEDICINAL AEROSOL FORUMLATIONS JAGO RESEARCH AG TOPICAL PHARMACEUTICAL GEL 12 684/MUM/2003 200339 05-08-2006 GLENMARK PHARMACEUTICALS LIMITED COMPOSITION FOR VALDECOXIB 13 1618/CAL/1997 200646 25-01-2007 SELECTIVE 3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY PYRIDAZINONE ALDOSE REDUCTASE 14 639/MUM NP/2003 200654 21/08/2006 PFIZER PRODUCT INC INHIBITOR A PHARMACEUTICAL PREPARATION FOR THE 15 492/MUM/2003 200878 06-07-2006 TREATMENT OF ADENOCARCINOMA OF SAHAJANAND BIOTECH PRIVATE LTD PROSTATE TRICYCLIC INHIBITOR OF POLY[ ADP- RIBOSE] 16 IN/PCT/2001/805/MUM 200884 06-08-2006 AGOURON PHARMACEUTICAL INC POLYMERS Imidazopyrimidine and triazolopyrimidine compounds 17 IN/PCT/2002/1413/MUM 200894 06-05-2006 BAYER AKTIENGESELLSCHAFT QUINOLINYL BENZOTHIAZALYL PPAR- 18 IN/PCT/2002/1890/MUM 200903 06-05-2006 TULARIK INC AND JAPAN TOBACCO INC, GAMMA MODULATOR "A CYTOTOXIC PEPTIDE HORMONE ADMINISTRATORS OF THE TULANE 19 635/CAL/1999 200945 19-01-2007 CONJUGATES" EDUCATIONAL FUND "1,3-DIHYDRO-1-(PHENYLALKYL)-2H- 20 588/CAL/1996 200946 19-01-2007 JANSSEN PHARMACEUTICA N.V. IMIDAZOL-2-ONE COMPOUNDS" CARBOXAMIDE DERIVATIVES AS NOVEL HIV 21 386/CAL/1998 201125 09-02-2007 PROTEASE INHIBITORS AND AGOURON PHARMACEUTICALS, INC. PHARMACEUTICAL COMPOSITIONS Topical Medicinal Spray Compositions And Their 22 43/MUM/2000 201134 06-05-2006 Preparations, Which Compositions Can Be Used To CIPLA LTD Treat A Variety Of Disorders 23 228/MUM/2000 201137 26/06/2006 A TOPICAL PHARMACEUTICAL COMPOSITION PFIZER INC 24 363/MUM/2003 201170 23/06/2006 NOVEL TRICYCLIC COMP AS DE 4 INHIBITOR KHARE SHRINIWAS RAMCHANDRA A SYNERGISTIC FORMULATION CONTAINING 25 257/MUM/2004 201173 08-01-2006 NONSTERODIAL ANALGESIC AND ANTI SANJEEV KHANDELWAL INFLAMMATORY PHARMACEUTICAL COMPOSITION FOR 26 800/CAL/1995 201217 16-03-2007 SOFOTEC GMBH & CO. KG ADMINISTRATION BY NHALATION 27 IN/PCT/2001/39/MUM 201231 13/09/2006 THIOBENZIMIDAZOLE DERV TEIJIN LTD A COMP OF BENZIMIDAZOLE AND 28 IN/PCT/2001/1538/MUM 201237 08-07-2006 JANSSEN PHARMACE UTICA NV IMIDAZOPYRIDINES NEW HETEROCYCLIC COMPOUND SOCIETE DE CONSEIL DE RECHERCHES ET D' 29 IN/PCT/2002/604/MUM 201240 08-07-2006 APP;LICATIOMN 30 IN/PCT/2002/671/MUM 201241 17/07/2006 ADAMANTANE DERV, ASTRAZENECA AB A COMP OF HOMOPIPERIDINYL SUBS 31 IN/PCT/2002/745/MUM 201242 14/07/2006 JANSSEN PHARMACE UTICA NV BENZIMIDAZOLE DERV, Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl- 32 IN/PCT/2002/922/MUM 201243 17/04/2006 2-[methyl(methylsulfonyl) amino] pyrimidin-5-yl]- ASTRAZENECA AB (3r,5s)-3,5-dihydroxyhept-6-enoic acid 33 IN/PCT/2002/1452/MUM 201251 17/07/2006 THE ETLA 4 MUTANT MOLECULE BRISTOL- MAYERS SQUIBB CO, A 2,3-dihydro-[1,4] dioxide – [2,3-b] pyridine 34 IN/PCT/2002/1547/MUM 201254 08-07-2006 compound of formula (I) and process of preparation JANSSEN PHARMACE UTICA NV thereof A THERAPEUTIC COMPOSTION BETH ISRAEL DEACONESS MEDICAL CENTER 35 IN/PCT/2002/1709/MUM 201259 08-07-2006 INC AN IODO PHENYLAMINO 36 28/MUM NP/2003 201268 08-07-2006 WARNER LAMBERT COMPANY BENZHYDROOXAMIC COMP, A COMPOSITION IN THE FORM OF AQ ORAL 37 168/MUMNP/2003 201276 08-07-2006 BAYER AKTIENGESELLSCHAFT SUSPENSION N-methyl-D-aspartic acid receptor antagonist 38 508/MUM NP/2003 201282 08-07-2006 PFIZER PRODUCT INC pharmaceutical compositions 39 801/MUM NP/2003 201284 08-07-2006 A metalloproteinase inhibitor compound ASTRAZENECA AB 40 802/MUM NP/2003 201285 08-07-2006 A metalloproteinase inhibitor compound ASTRAZENECA AB 41 189/CAL/1995 201469 08-07-2006 ORAL FORMULATION OF AN ANTIFUNGAL JANSSEN PHARMACE UTICA NV A CYCLIC SOMATOSTATIN HEXAPEPTIDE AND 42 1094/MAS/1996 201579 31-08-2006 NOVARTIS AG PHARMACEUTICAL COMP, NOVEL SUCCINATE SALT OF O-DESMETHYL- 43 1015/KOLNP/2003 201649 16-02-2007 WYETH VENLAFAXINE "A COMPOUND WITH ANTIBACTERIAL 44 IN/PCT/2002/00246/KOL 201928 23-03-2007 SANKYO COMPANY LIMITED ACTIVITY" 45 141/MUM/2000 201976 31/08/2006 A NOVEL BIARYL ETHER COMP, PFIZER PRODUCT INC 46 168/MUM/2003 202014 21/06/2006 INHALENT COMPOSITION CIPLA LTD 47 1290/MAS/1998 202050 12-09-2006 BENZO 5,6 CYCLOPHEPT PYRIDINE DERV SCHERING CORPORATION A PHARMACEUTICAL COMPOSITION IN THE 48 916/MAS/1998 202053 21-09-2006 RECKITT BENCKISER HEALTHCARE LIMITED. FORM OF AQUOUS PURABLE LIQUID COMPOSITION CONTAINING RURHENIUM (iii)) FAUSTUS FORSCHUNGS CIE 49 1300/CHENP/2003 202076 08-09-2006 COMPLEX AND HETEROCYCLIC TRANSLATIONAL CANCER RESEARCH GMBH 50 2479/MAS/1998 202085 21-09-2006 DIPEPTIDE NITRILES M/S. NOVARTIS AG A PHARMACEUTICAL COMPOSITION FOR 51 1678/CHENP/2003 202097 21-09-2006 JAPAN TOBACCO, INC., INFLAMMATORY BOWEL DISEASE 2-(3-5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6- (1,1-DIOXO-1 6- THIOMORPHOLIN-4-YL)-4-(2- 52 188/CHENP/2004 202106 05-09-2006 METHYL OR 4-FLUORO-2-METHYL F. HOFFMANN-LA ROCHE AG SUBSTITUTED) PHENYL-PYRIDIN-3-YL]-N- METHYL-ISOBUTYRAMIDE 53 2232/MAS/1998 202128 13-10-2006 CRYSTALLINE ANTIFUNGAL POLYMORPHS SCHERING CORPORATION 54 2433/MAS/1997 202141 05-09-2006 NAPHTHYRIDINE DERV NOVARTIS AG CYCLOPENTANOINDOLES, COMPOSITIONS 55 245/CHENP/2003 202142 05-09-2006 M/S. MERCK FROSST CANADA & CO. CONTAINING SUCH COMPOUNDS A 7-AMINOTRIAZOLOPYRIMIDINE AND A 56 384/CHENP/2004 202191 21-09-2006 BASF AKTIENGESELLSCHAFT PROCESS FOR PREPARING THE SAME A PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF HEPATITIS & VIRAL 57 405/MAS/1999 202193 03-10-2006 UNIVERSITY OF MADRAS INFECTIONS AND A PROCESS FOR ITS PREPARATION A PHARMACEUTICAL COMPOSITION FOR THE 58 534/MAS/1996 202212 12-09-2006 ORAL ADMINISTRATION OF AN ACTIVE CIBA-GEIGY AG AGENT HAVING LOW WATER SOLUBILITY COMPOSITION FOR TREATING RESPIRATORY 59 IN/PCT/2000/109/CHE 202273 21-09-2006 SCHERING CORPORATION AND SKIN DISEASES PHARMACEUTICAL COMPOSITIONS 60 IN/PCT/2002/00475/MUM 202295 11-09-2006 PROVIDING ENHANCED DRUG PFIZER PRODUCTS INC. CONCENTRATIONS 61 1119/MUM NP/2003 202297 04-08-2006 DOSAGE REGIMEN AND PHARMACEUTICAL RICHTER GEDEON VEGYESZETI GYAR RT, COMPOSITIONS CONTAINING 62 IN/PCT/2002/01658/MUM 202304 11-08-2006 BAYER AKTIENGESELLSCHAFT POLYCARBONATE A LIQUID NASAL PHARMACEUTICAL 63 IN/PCT/2000/75/CHE 202344 31-10-2006 NOVARTIS CONSUMER HEALTH S.A COMPOSITION CARBAMIC ACID DERIVATIVES AND THEIR 64 IN/PCT/2001/1424/CHE 202354 11-10-2006 USE AS METABOTROPIC GLUTAMATE M/S. F. HOFFMANN-LA ROCHE AG RECEPTOR LIGANDS A PIPERIDINE DERIVATIVE AND A 65 IN/PCT/2001/1516/CHE 202356 09-10-2006 PHARMACEUTICAL COMPOSITION M/S. SCHERING CORPORATION COMPRISING THE SAME 66 IN/PCT/2001/519/CHE 202372 03-10-2006 THE PHARMACEUTICAL COMPOSITION M/S. NOVARTIS AG SUBTILASE SUBTILASE ENZYMES OF THE I S I AND IS2 SUB GROUPS HAVING AN 67 IN/PCT/2001/819/CHE 202383 31-10-2006 ADDITIONAL AMINO ACID AN ACTIVE NOVOZYMES A/S SITELOOP AND A METHOD OF PRODUCING THE SAME 68 IN/PCT/2002/336/CHE 202425 13-04-2007 A VACCINE COMPOSITION SMITHKLINE BEECHAM BIOLOGICALS S.A. 69 IN/PCT/2002/683/CHE 202441 04-10-2006 TRIPHENYLALKENE DERIVATIVES M/S. HORMOS MEDICAL CORPORATION 70 587/CAL/1996 202521 23-02-2007 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE JANSSEN PHARMACEUTICA N.V DELTA <9> TETRAHYDROCANNABINOL ( 71 IN/PCT/2001/385/KOL 202523 02-03-2007 DELTA <9> THC) SOLUTION METERED DOSE VIRGINIA COMMONWEALTH UNIVERSITY INHALERS AND METHODS OF USE COMPOSITIONS FOR THE PREVENTION OF 72 IN/PCT/2001/480/KOL 202527 02-03-2007 TOLERANCE TO MEDICATIONS AND METHODS BAKER NORTON PHARMACEUTICALS ,INC. OF PREPARATION THEREOF" "GROWTH HORMONE RELEASING 73 425/KOLNP/2003 202530 02-03-2007 ZENTARIS AG COMPOUNDS AND THEIR ANTAGONISTS" "4-(1H-INDOL-1-YL)-1-PIPERIDINYL 74 121/CAL/1996 202659 02-03-2007 JANSSEN PHARMACEUTICAL N.V. DERIVATIVES" 75 605/KOLNP/2003 202663 02-03-2007 " L-HISTIDINE IN OPHTHALMIC SOLUTIONS " BIO CONCEPT LABOTORIES PHARMACEUTICAL COMPOSITION FOR 76 495/MUM/2002 202692 20/07/2006 J B CHEMICAL & PHARMACEUTICALS LTD CONTROLLED DRUG DELIVERY SYSTEM INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR 77 IN/PCT/2002/00589/MUM 202735 03-10-2006 AGOURON PHARMACEUTICAL INC MEDIATING OR INHIBITING CELL PROLIFERATION 78 IN/PCT/2002/673/MUM 202748 07-09-2006 AN AMINOTHIAZOLE INHIBITOR COMPOUND BRISTOL- MAYERS SQUIBB CO, NOVEL TRANS-LUTEIN ENRICHED M/S.
Load more

Recommended publications
  • United States Securities and Exchange Commission Form
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2020 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 2000 Galloping Hill Road, Kenilworth, NJ 07033 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (908) 740-4000 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    [Show full text]
  • Basic Science of ITP
    CHAPTER 1 Basic sc*ience of ITP Editor: John W. Semple 1.1 Megakaryocyte differentiation and platelet produc*tion A.S. Weyrich 1.2 Autoimmune mechanisms and T regula*tory cell disturbances in ITP K. Yazdanbakhsh 1.3 Mouse models o*f ITP J.W. Semple 1.4 Peptide therapy for patients with* ITP S.J. Urbaniak * Basic science of ITP 1.1 Megakaryocyte differen*tiation and platelet production Andrew S. Weyrich CHAPTER 1.1 • Megakaryocyte differentiation and platelet production 1. Introduction Platelets are anucleate cells that circulate in the bloodstream for approximately 10 days. The average adult must produce roughly 1 x 10 11 platelets per day to maintain normal platelet counts, a level of production that increases dramatically in a variety of clinical scenarios (1). In 1906, Wright provided the first evidence that megakaryocytes give rise to blood platelets. Since then, our understanding of the molecular basis of thrombopoiesis has progressed substantially and is arguably in a logarithmic growth phase. This chapter will review our current understanding of thrombopoiesis and highlight how the field is evolving. The history of megakaryocytes and platelets is fairly young. In 1841, Addison first described platelets and in 1882, Bizzozero named and identified platelets in the circulation and determined that they could induce clotting. In 1890, Howell named megakaryocytes, and 16 years later, Wright discovered that these were actually the precursors of platelets. Thus, the late 1880’s and early 1900’s were a period of prolific activity in the elucidation of megakaryocytes. Several discoveries were made about platelets and also about erythropoietin, which implied that a humoral substance also regulated platelet production though its exact nature was not yet known.
    [Show full text]
  • Specialists in Small Molecule Drug Development
    Specialists in Small Molecule Drug Development Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO & Co-Founder Final Results for the Year Ending 30 June 2019 October 2019 www.sareum.co.uk Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Order, or (iii) those persons to whom it can otherwise be distributed without contravention of article 21 of the Financial Services and Markets Act 2000 (“FISMA”) or to whom it can lawfully be distributed. This Presentation has been prepared by Sareum Holdings PLC (“Company”) and provided to you for information purposes only. This Presentation is not an invitation or inducement to engage in an investment activity for the purposes of FISMA. This Presentation has not been approved by an Authorised Person (as defined in s31 FISMA), as would be required for financial promotions under s21 FISMA and, for the avoidance of doubt, is not a financial promotion for the purposes of FISMA. If, contrary to the above, this Presentation is deemed to be a financial promotion for the purposes of FISMA, the Company relies on the exemptions set out in Articles 19, 43, 59 and 69 of the Order, which exempts companies admitted to trading on relevant markets making certain communications. Please note that any indication of past performance should not be relied upon as a guide to future performance.
    [Show full text]
  • News Release
    News Release ____________________________________________________________________________ FOR IMMEDIATE RELEASE Media Contacts: Tracy Ogden Investor Contacts: Teri Loxam (908) 740-1747 (908) 740-1986 Claire Gillespie Michael DeCarbo (267) 305-0932 (908) 740-1807 Merck Announces First-Quarter 2018 Financial Results First-Quarter 2018 Worldwide Sales Were $10.0 Billion, an Increase of 6 Percent, Including a 3 Percent Positive Impact from Foreign Exchange First-Quarter 2018 GAAP EPS was $0.27, Reflecting a $1.4 Billion Aggregate Charge Related to the Formation of a Collaboration with Eisai; First-Quarter Non-GAAP EPS was $1.05 Company Narrows and Raises 2018 Full-Year Revenue Range to be Between $41.8 Billion and $43.0 Billion, Including an Approximately 2 Percent Positive Impact from Foreign Exchange Company Lowers 2018 GAAP EPS Range to be Between $2.45 and $2.57; Narrows and Raises 2018 Full-Year Non-GAAP EPS Range to be Between $4.16 and $4.28, Including an Approximately 1 Percent Positive Impact from Foreign Exchange Results from Phase 3 KEYNOTE-189 Study Presented at AACR 2018 and Published in The New England Journal of Medicine Showed KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous NSCLC Data from KEYNOTE-189 is Now Under Review by Regulatory Authorities in the United States, Europe and Japan KENILWORTH, N.J., May 1, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2018. “Merck had a strong start to the year driven by KEYTRUDA, GARDASIL, BRIDION and Animal Health,” said Kenneth C.
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 26, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2020: 2,536,268,760. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2019 based on closing price on June 30, 2019: $215,106,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • 2018 Medicines in Development for Skin Diseases
    2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • 2019 Analyst Day
    2019 Analyst Day March 12, 2019 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it’s partners’ judgment as of the date of this presentation. Words such as “plans,” “believes,” “expects,” “projects,” “could,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial projections, expectations regarding research and development programs, potential uses of capital, including any potential dividend or share repurchase program, and the timing of the initiation or compilation of preclinical studies and clinical trials by Ligand and its partners. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherit in Ligand’s business, including: Ligand has wide discretion on its use of capital and may choose not to engage in any share repurchases, declare any dividends or pursue acquisitions or internal develop programs; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline;, drug development program benefits may not be realized; Ligand will achieve its guidance in 2019 or thereafter; third party research summarized herein may not be correct or complete; Kyprolis®, EVOMELA® and Zulresso™ may not perform as expected, Ligand relies on collaborative partners for milestone and royalty payments,
    [Show full text]